Unternehmen in HANNOVER

MOSAIQUES DIAGNOSTICS GMBH

BeobachtenFeed abonnierenFörderungen als CSV

In 0 Bekanntmachungen genannt, seit 1. Januar 2010, aber in keiner als Auftragnehmer eines Zuschlags.

Fördermittel

Kohesio und Finanztransparenzsystem der EU, so gezählt.

41 Förderungen, zusammen 13,2 Mio. €.

QuelleBetragFörderungen
EU-Haushalt (Finanztransparenzsystem)13,2 Mio. €4141
JahrProgrammProjektBetrag und Beleg
2024EU Budget - European CommissionREA - European Research Executive Agency101169245 - PROMOTE - PROSTATE CANCER OMICS ORIENTED INTERVENTION101169245 - PROMOTE - PROSTATE CANCER OMICS ORIENTED INTERVENTION521.077 €Mittelbindung
2024EU Budget - European CommissionREA - European Research Executive Agency101168626 - PICKED - PERSONALIZED MEDICINE IN CHRONIC KIDNEY DISEASE101168626 - PICKED - PERSONALIZED MEDICINE IN CHRONIC KIDNEY DISEASE260.538 €Mittelbindung
2023EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE202.253 €Mittelbindung
2023EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE24.330 €Mittelbindung
2023EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE500.404 €Mittelbindung
2023EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE101136926 - MULTIR - MULTI-TUMOUR BASED PREDICTION AND MANIPULATION OF IMMUNE RESPONSE9.715 €Mittelbindung
2022EU Budget - European CommissionREA - European Research Executive Agency101072828 - DISCO-I - DISCOVERING COLLAGEN I DEGRADATION PROCESS IN CHRONIC DISEASES WITH FIBROTIC COMPONENT101072828 - DISCO-I - DISCOVERING COLLAGEN I DEGRADATION PROCESS IN CHRONIC DISEASES WITH FIBROTIC COMPONENT521.079 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101097094 - ELMUMY - ELUCIDATION OF RISK FACTORS AND HEALTH DETERMINANTS ASSOCIATED WITH PROGRESSION OF MONOCLONAL GAMMOPATHIES TO MULTIPLE MYELOMA101097094 - ELMUMY - ELUCIDATION OF RISK FACTORS AND HEALTH DETERMINANTS ASSOCIATED WITH PROGRESSION OF MONOCLONAL GAMMOPATHIES TO MULTIPLE MYELOMA357.459 €Mittelbindung
2022EU Budget - European CommissionHADEA - European Health and Digital Executive Agency101097094 - ELMUMY - ELUCIDATION OF RISK FACTORS AND HEALTH DETERMINANTS ASSOCIATED WITH PROGRESSION OF MONOCLONAL GAMMOPATHIES TO MULTIPLE MYELOMA101097094 - ELMUMY - ELUCIDATION OF RISK FACTORS AND HEALTH DETERMINANTS ASSOCIATED WITH PROGRESSION OF MONOCLONAL GAMMOPATHIES TO MULTIPLE MYELOMA154.275 €Mittelbindung
2020EU Budget - European CommissionREA - European Research Executive Agency860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.224.122 €Mittelbindung
2020EU Budget - European CommissionREA - European Research Executive Agency860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.16.026 €Mittelbindung
2020EU Budget - European CommissionREA - European Research Executive Agency860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.860329 - STRATEGY-CKD - SYSTEM OMICS TO UNRAVEL THE GUT-KIDNEY AXIS IN CHRONIC KIDNEY DISEASE.12.639 €Mittelbindung
2020EU Budget - European CommissionREA - European Research Executive Agency898260 - REDRUGBC - NOVEL THERAPEUTIC APPROACHES, BASED ON DRUG REPURPOSING, FOR HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER DRIVEN BY PATIENTS PROTEOMIC SIGNATURES898260 - REDRUGBC - NOVEL THERAPEUTIC APPROACHES, BASED ON DRUG REPURPOSING, FOR HIGH RISK NON MUSCLE INVASIVE BLADDER CANCER DRIVEN BY PATIENTS PROTEOMIC SIGNATURES162.806 €Mittelbindung
2019EU Budget - European CommissionRTD - Directorate-General for Research and Innovation848011 - DC-REN - DRUG COMBINATIONS FOR REWRITING TRAJECTORIES OF RENAL PATHOLOGIES IN TYPE II DIABETES (DC-REN)848011 - DC-REN - DRUG COMBINATIONS FOR REWRITING TRAJECTORIES OF RENAL PATHOLOGIES IN TYPE II DIABETES (DC-REN)11.746 €Mittelbindung
2019EU Budget - European CommissionRTD - Directorate-General for Research and Innovation848011 - DC-REN - DRUG COMBINATIONS FOR REWRITING TRAJECTORIES OF RENAL PATHOLOGIES IN TYPE II DIABETES (DC-REN)848011 - DC-REN - DRUG COMBINATIONS FOR REWRITING TRAJECTORIES OF RENAL PATHOLOGIES IN TYPE II DIABETES (DC-REN)689.306 €Mittelbindung
2018EU Budget - European CommissionREA - European Research Executive Agency800048 - PCAPROTREAT - MULTI-OMICS MOLECULAR TREATMENT TARGETS FOR PROSTATE CANCER800048 - PCAPROTREAT - MULTI-OMICS MOLECULAR TREATMENT TARGETS FOR PROSTATE CANCER171.461 €Mittelbindung
2018EU Budget - European CommissionREA - European Research Executive Agency799993 - PROCEED - PROTEOMICS FOR CHRONIC KIDNEY DISEASE THERAPY799993 - PROCEED - PROTEOMICS FOR CHRONIC KIDNEY DISEASE THERAPY171.461 €Mittelbindung
2017EU Budget - European CommissionREA - European Research Executive Agency764474 - CARESYAN - COMBATTING THE CARDIORENAL SYNDROME: TOWARDS AN INTEGRATIVE ANALYSIS TO REDUCE CARDIOVASCULAR BURDEN IN CHRONIC KIDNEY DISEASE764474 - CARESYAN - COMBATTING THE CARDIORENAL SYNDROME: TOWARDS AN INTEGRATIVE ANALYSIS TO REDUCE CARDIOVASCULAR BURDEN IN CHRONIC KIDNEY DISEASE249.216 €Mittelbindung
2017EU Budget - European CommissionX - EACI - Executive Agency for Competitiveness and Innovation739709 - THERANOMICS - INTEGRATION OF HIGH RESOLUTION -OMICS DATASETS TOWARDS PERSONALIZED THERAPY IN BLADDER CANCER739709 - THERANOMICS - INTEGRATION OF HIGH RESOLUTION -OMICS DATASETS TOWARDS PERSONALIZED THERAPY IN BLADDER CANCER116.250 €Mittelbindung
2017EU Budget - European CommissionREA - European Research Executive Agency752755 - BIOMEDBC - MOLECULAR PROFILING OF BLADDER CANCER TO SUPPORT PERSONALIZED MEDICINE752755 - BIOMEDBC - MOLECULAR PROFILING OF BLADDER CANCER TO SUPPORT PERSONALIZED MEDICINE159.461 €Mittelbindung
2016EU Budget - European CommissionREA - European Research Executive Agency721746 - TRANSPOT - TRANSLATIONAL RESEARCH NETWORK IN PROSTATE CANCER721746 - TRANSPOT - TRANSLATIONAL RESEARCH NETWORK IN PROSTATE CANCER249.216 €Mittelbindung
2016EU Budget - European CommissionRTD - Directorate-General for Research and InnovationHOMAGE - HEALTH-F5-2012-305507 - "HEART OMICS IN AGEING" - FP-7 RTD PROJECTHOMAGE - HEALTH-F5-2012-305507 - "HEART OMICS IN AGEING" - FP-7 RTD PROJECT0 €Mittelbindung
2015EU Budget - European CommissionREA - European Research Executive Agency642937 - RENALTRACT - DEVELOPMENT AND DISEASE OF THE RENAL TRACT642937 - RENALTRACT - DEVELOPMENT AND DISEASE OF THE RENAL TRACT249.216 €Mittelbindung
2015EU Budget - European CommissionREA - European Research Executive Agency690966 - PRETREAT - PROTEOME-BASED ASSESSMENT OF VASCULAR DISEASE FOR THE ESTABLISHMENT OF A TRANSLATIONAL RESEARCH PLATFORM690966 - PRETREAT - PROTEOME-BASED ASSESSMENT OF VASCULAR DISEASE FOR THE ESTABLISHMENT OF A TRANSLATIONAL RESEARCH PLATFORM126.000 €Mittelbindung
2015EU Budget - European CommissionRTD - Directorate-General for Research and InnovationHEALTH-F2-2009-241544 - SYSKIDHEALTH-F2-2009-241544 - SYSKID0 €Mittelbindung

Angaben aus den Bekanntmachungen

0 Nennungen seit 1. Januar 2010, zuletzt am 1. Januar 2010, dieser Organisation zugeordnet. Wie wir zuordnen

Anschrift
MELLENDORFER STRASSE 7 9, 30625 HANNOVER
USt-IdNr.
DE213022344
Schreibweisen
  • MOSAIQUES DIAGNOSTICS GMBH